Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
暂无分享,去创建一个
E. Perucca | E. Spina | M. Dahl | M. G. Scordo | G. Gatti
[1] R. Berecz,et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions , 2004, European Journal of Clinical Pharmacology.
[2] M. Ansseau,et al. Polymorphisms in the CYP 2D6 Gene: Association with Plasma Concentrations of Fluoxetine and Paroxetine , 2003, Therapeutic drug monitoring.
[3] E. Perucca,et al. Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[4] E. Spina,et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance , 2002, Clinical pharmacology and therapeutics.
[5] P. Magni,et al. Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine: Sources of Variability and Preliminary Observations on Relations With Clinical Response , 2002, Therapeutic drug monitoring.
[6] L. Bertilsson,et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.
[7] Erik Eliasson,et al. Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype , 2002, Clinical pharmacology and therapeutics.
[8] Zhaoqian Liu,et al. O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. , 2002, The Journal of pharmacology and experimental therapeutics.
[9] M. Ingelman-Sundberg,et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. , 2001, British journal of clinical pharmacology.
[10] J. Goldstein,et al. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.
[11] H. Zhou,et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. , 2001, British journal of clinical pharmacology.
[12] C. Eap,et al. Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers , 2001, Journal of clinical psychopharmacology.
[13] S. Binkley,et al. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. , 2001, The Journal of pharmacology and experimental therapeutics.
[14] M. Reis,et al. Serum Concentrations of Fluoxetine in the Clinical Treatment Setting , 2001, Therapeutic drug monitoring.
[15] H. Zhou,et al. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. , 2001, Acta pharmacologica Sinica.
[16] S. Ekins,et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[17] C. Alm,et al. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. , 1999, Pharmacogenetics.
[18] K. Brøsen,et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. , 1999, Pharmacogenetics.
[19] M. Ingelman-Sundberg,et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.
[20] M. Ingelman-Sundberg,et al. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. , 1999, Gene.
[21] Joe C. Watson,et al. Report from the Second European Stroke Summer School, Heidelberg, Germany , 1999, Cerebrovascular Diseases.
[22] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[23] A. Holtz,et al. Fluoxetine tenth anniversary update: the progress continues. , 1997, Clinical therapeutics.
[24] D. Greenblatt,et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro , 1997, Psychopharmacology.
[25] J. Brockmöller,et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.
[26] J. Turgeon,et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin , 1996, Clinical pharmacology and therapeutics.
[27] W. Trager,et al. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.
[28] G R Wilkinson,et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.
[29] A. Altamura,et al. Clinical Pharmacokinetics of Fluoxetine , 1994, Clinical pharmacokinetics.
[30] L. Wienkers,et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.
[31] S. Wrighton,et al. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. , 1993, The Journal of pharmacology and experimental therapeutics.
[32] D. Wong,et al. Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain , 1993, Neuropsychopharmacology.
[33] R. Fuller,et al. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo , 1992, Neuropharmacology.
[34] U. Meyer,et al. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.
[35] D. Wong,et al. Inhibition of serotonin uptake by optical isomers of fluoxetine , 1985 .